Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06304467 · ClinicalTrials.gov registry record · NA

CM for Patients With ALD After Liver Transplant

A NA study of Alcohol Use Disorder and Contingency Management, sponsored by Arpan A. Patel, MD.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06304467 is a NA study of Alcohol Use Disorder and Contingency Management that is actively recruiting participants, run by Arpan A. Patel, MD. The registered enrollment target is 30 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06304467, a NA study of Alcohol Use Disorder and Contingency Management, is actively recruiting participants, sponsored by Arpan A. Patel, MD.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Alcohol associated liver disease (ALD) refers to liver injury, such as cirrhosis, that is caused by alcohol use. It affects 2 million adults in the U.S. and is now the leading cause of cirrhosis-related hospitalizations, cirrhosis- related deaths, and liver transplantation. Alcohol use disorder (AUD), the root cause of ALD, affects 15 million Americans each year. While research studies have shown that behavioral therapy and medications specific for alcohol use have helped people overcome their alcohol use disorder, there has not been enough information related to how successful these treatments are specifically for people with ALD. This study will look at a behavioral treatment called "contingency management" (CM) that has shown to be effective with people with other substance use disorders. CM is based on the principles of operant conditioning that involves offering prize-based or monetary incentives to patients with substance use disorders to reduce substance use. This study will look at the efficacy and acceptability of CM in patients who received a liver transplant and have evidence of recurrent alcohol use. The proposed study is a pilot randomized controlled trial of 30 patients with ALD who received a liver transplant; 15 will be randomized to receive a 10-week CM intervention while 15 will receive treatment as usual (TAU or control). Subjects will be asked to complete 12 study visits (including Screening and Baseline Visits) that will last 1 to 2 hours each depending on the visit. All visits will be completed via Zoom or by phone. Study staff will instruct participants on how to use Zoom, if necessary. During the Screening and Baseline Visits, subjects will be: 1) asked to provide a urine test and blood draw, 2) complete the SCID-5 AUD, a semi-structured interview guide for making the major DSM-5 diagnoses, 3) complete the Iowa Gambling Test which looks at decision-making skills, 4) complete a survey that looks at the subject's quality of life after liver tr

Interventions

  • BEHAVIORAL Contingency Management

Study Locations (1)

California

  • Pfleger Liver Institute - Los Angeles

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-09-17
Est. Completion 2026-09-01
Phase NA

Sponsor

Arpan A. Patel, MD

1 total trials

What the Registry Record Tells You About NCT06304467

The ClinicalTrials.gov registry entry for NCT06304467 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (91% lower). The listed sponsor is Arpan A. Patel, MD, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Alcohol Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Contingency Management is the first listed.

NCT06304467 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06304467 about?

NCT06304467 is a clinical study titled "CM for Patients With ALD After Liver Transplant". Alcohol associated liver disease (ALD) refers to liver injury, such as cirrhosis, that is caused by alcohol use. It affects 2 million adults in the U.S. and is now the leading cause of cirrhosis-related hospitalizations, cirrhosis- related deaths, and liver transplantation. Alcohol use disorder (AUD...

What is the current status of trial NCT06304467?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-09-17. Estimated completion is 2026-09-01.

What conditions does trial NCT06304467 study?

This clinical trial studies the following conditions: Alcohol Use Disorder, Contingency Management, Post Liver Transplant, Alcohol Liver Disease, Alcohol; Liver.

What interventions are being tested in trial NCT06304467?

The interventions under investigation include: Contingency Management (BEHAVIORAL).

Who is sponsoring clinical trial NCT06304467?

This trial is sponsored by Arpan A. Patel, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06304467 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcohol Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.